Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties' 2025 oncology biosimilars partnership SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.

Swiss generic drugmaker Sandoz will pay up to $77 million ​upfront to Shanghai Henlius Biotech for rights to ‌three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.

Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript

Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.

Swiss generic ​maker Sandoz ‌reported a 9% jump ​in second ​quarter net sales ⁠on Wednesday, ​slightly above ​analyst expectations, as it reaped ​the benefits ​of patent expirations ‌in ⁠its biosimilars unit.

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?